| Clinical Trial Name | Clinical Trial Full Title | Principal Investigator | Project site status | Clinical trials gov number |
|---|---|---|---|---|
| (Merck) MK-3475-587 / KEYNOTE 587 | A Multicenter, Open label, Phase III Extension Trial to Study the Long-term Safety and Efficacy in Participants with Advanced Tumors Who Are Currently on Treatment or in Follow-up in a Pembrolizumab Trial | McWhirter, Dr Elaine | Open to recruitment | NCT03486873 |
| (HHS) CRUSSH | Stereotactic body radiotherapy (SBRT) boost following urgent 3D conformal radiotherapy in the treatment of metastatic epidural spinal cord compression (SCC): A phase I feasibility trial | Donovan, Dr Elysia | Open to recruitment | NCT03529708 |
| (IMV) Immunovac / P1719-SUR-Z11 | A Phase 2, Open-label, Multicenter, Study of an Immunotherapeutic Treatment, DPX-Survivac in combination with Low Dose Cyclophosphamide and Pembrolizumab, in Subjects with Selected Advanced and Recurrent Solid Tumours | Hirte, Dr Hal | Open to recruitment | NCT03836352 |
| (Tesaro) 4010-01-001 / GARNET | A Phase 1 Dose Escalation and Cohort Expansion Study of TSR-042, an anti-PD-1 Monoclonal Antibody, in Patients with Advanced Solid Tumors | Elit, Dr Laurie | Open to recruitment | NCT02715284 |
| (Ayala) AL-ACC-01 / ACCURACY | A Phase 2, Open-Label, Single-Arm, Multi-Center Study Of AL101 (BMS-906024) In Patients With Adenoid Cystic Carcinoma (ACC) Bearing Activating Notch Mutations | Hotte, Dr Sebastien | Open to recruitment | NCT03691207 |
| (Debio) 1143-NSCLC-105 | A phase-Ib dose-finding study of the SMAC mimetic Debio 1143 when given in combination with the anti-PD-L1 antibody avelumab to patients with advanced solid malignancies and, in an expansion cohort, to patients with advanced or metastatic Non-Small Cell Lung Cancer (NSCLC) after platinum-based therapy | Juergens, Dr Rosalyn | Open to recruitment | NCT03270176 |
| (UHN) OCTANE | Ontario-wide Cancer TArgeted Nucleic acid Evaluation (OCTANE) | Hotte, Dr Sebastien | Suspended/On hold | NCT02906943 |
| (CCTG) IND.238 | A Phase II Study of Durvalumab Retreatment in Patients who Discontinued Prior Checkpoint Therapy Due to Immune Related Toxicity | Ellis, Dr Peter | Suspended/On hold | NCT03847649 |
| (AstraZeneca) D4191C00068 / STRONG | An Open-Label, Multi-Centre, Safety Study of Fixed-Dose Durvalumab + Tremelimumab Combination Therapy or Durvalumab Monotherapy in Advanced Solid Malignancies (STRONG) – Core Protocol; Module A – Post-Chemotherapy Urothelial and NonUrothelial Carcinoma of the Urinary Tract | Hotte, Dr Sebastien | Suspended/On hold | NCT03084471 |
Find a Trial
Contact Us